Cargando…
Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies
This evidence-based review will discuss the current standard of adjuvant chemotherapy for resected high-risk colon cancer and address existing controversies including strategies for risk-stratification, the status of targeted therapy, treatment of the elderly and the optimal duration of therapy.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202614/ https://www.ncbi.nlm.nih.gov/pubmed/25336789 http://dx.doi.org/10.4103/0971-5851.142032 |
| _version_ | 1782340323970646016 |
|---|---|
| author | Gill, Sharlene |
| author_facet | Gill, Sharlene |
| author_sort | Gill, Sharlene |
| collection | PubMed |
| description | This evidence-based review will discuss the current standard of adjuvant chemotherapy for resected high-risk colon cancer and address existing controversies including strategies for risk-stratification, the status of targeted therapy, treatment of the elderly and the optimal duration of therapy. |
| format | Online Article Text |
| id | pubmed-4202614 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42026142014-10-21 Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies Gill, Sharlene Indian J Med Paediatr Oncol Comments and Controversies This evidence-based review will discuss the current standard of adjuvant chemotherapy for resected high-risk colon cancer and address existing controversies including strategies for risk-stratification, the status of targeted therapy, treatment of the elderly and the optimal duration of therapy. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4202614/ /pubmed/25336789 http://dx.doi.org/10.4103/0971-5851.142032 Text en Copyright: © Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Comments and Controversies Gill, Sharlene Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title_full | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title_fullStr | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title_full_unstemmed | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title_short | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| title_sort | adjuvant therapy for resected high-risk colon cancer: current standards and controversies |
| topic | Comments and Controversies |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202614/ https://www.ncbi.nlm.nih.gov/pubmed/25336789 http://dx.doi.org/10.4103/0971-5851.142032 |
| work_keys_str_mv | AT gillsharlene adjuvanttherapyforresectedhighriskcoloncancercurrentstandardsandcontroversies |